Home
Mobile version
spiked plus
About spiked
What is spiked?
Support spiked
spiked shop
Contact us
Advertising
Summer school
Top issues
Abortion
Arab uprisings
British politics
Child abuse panic
Economy
Environment
For Europe, Against the EU
Free speech
Jimmy Savile scandal
Nudge
Obesity
Parents and kids
Population
USA
View all issues...
special feature
The Counter-Leveson Inquiry
other sections
 Letters
 Review of Books
 Monthly archive
selected authors
Duleep Allirajah
Daniel Ben-Ami
Tim Black
Jennie Bristow
Sean Collins
Dr Michael Fitzpatrick
Frank Furedi
Helene Guldberg
Patrick Hayes
Mick Hume
Rob Lyons
Brendan O’Neill
Nathalie Rothschild
James Woudhuysen
more authors...
RSS feed
survey
a-b c-d e-h i-l m-n o-r s-u v-z index
Dr Richard Sullivan
director of clinical programmes and centres at Cancer Research UK, and chair of the European Cancer Research Managers Forum


Demographic changes mean that cancer incidence will dramatically increase over the next twenty years as developed countries feel the burden of an ageing population. In addition, and despite substantial reductions in many countries the scourge of tobacco will continue to be reaped in developed countries and increasingly in developing countries. Strategies for cancer control will need to be twin tracked - socio-political to deal with tobacco control and scientific to address the need for cost-effective anti-cancer treatments. The next twenty years will need to shift to a fundamentally anti-tobacco culture that moves beyond simple legislation. Society needs to address the pervasive addiction and image of tobacco as a social emollient. When members of the public see tobacco in the same light as asbestos then it will be under control.

Despite great advances in the control and cure of cancer so many areas remain out-of-reach. For example there has been glacial progress against almost all types of metastatic disease. In addition over-treatment and under-treatment remain commonplace as we have few practical ways of predicting who will respond to treatment and who will develop toxicities. The personalisation of treatment is not only the grail for cancer research, but remains the only hope of ensuring that increasingly expensive treatments are affordable to society. Even when we have mastered the complexities of death in old age whether through cancer, or other degenerative disease, all our advances over the next twenty years must not be at the expense of providing a pain-free and dignified death to all.



Survey home
What we found
Survey responses
Feedback
RSS feed
Anjana Ahuja
Michael Baum
Peter Cochrane
Richard Feachem
Frank Furedi
Michio Kaku
Ken MacLeod
Jonathan Meades
Munira Mirza
Matthew Parris
Ingo Potrykus
Roger Scruton
Ben Shneiderman
Lionel Shriver
Raymond Tallis
Peter Whittle
Josie Appleton
David Baulcombe
Claire Fox
William Higham
Paul Lauterbur
William Graeme Laver
Ken MacLeod
Fiona McEwen
Victor Stenger